Arbutus Biopharma Corporation (NASDAQ:ABUS) and Genevant have sued Moderna Inc (NASDAQ:MRNA) for infringing on their patent on a lipid nanoparticle platform that they say was crucial to the delivery of Moderna’s widely-used COVID-19 vaccine.
The companies are seeking an award of damages sufficient to compensate Arbutus and Genevant for Moderna’s infringement under 35 U.S.C. §284, in no event less than a reasonable royalty on all infringing sales or other dispositions of Accused Product.
